Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Myocet Stories

2014-04-17 16:26:55

LAGUNA HILLS, Calif., April 17, 2014 /PRNewswire/ -- NanoSmart(®) and NanoValent, private pharmaceutical companies developing novel cancer pharmaceuticals, have entered into a research collaboration agreement to explore the feasibility of jointly developing an ANA-conjugated liposomal doxorubicin nanoparticle for the treatment of ovarian cancer and other solid tumors. The joint project combines NanoValent's hybrid polymerized liposomal nanoparticle (HPLN), which can be loaded with...

2013-12-12 10:59:30

98.7 percent are cancer free for at least 3 years A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol, a study has found. The study is the first major trial to examine the Herceptin-Taxol combination in patients who have a type of breast cancer with the biology known as small, node-negative, HER2+. Results were presented during the 2013 San Antonio Breast Cancer...

2013-03-08 23:04:38

A recent FDA-approved combination of therapies used to target HER2-positive breast cancer does not lead to increased cardiac problems for patients, but doctors should regularly perform cardiac monitoring on their cancer patients until additional long-term cardiac safety data become available, according to the first phase III study of the combined treatments. The study, published in The Oncologist, was led by Dr. Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at...

2013-01-31 08:29:54

LAWRENCEVILLE, N.J., Jan. 31, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that ThermoDox® in combination with radiofrequency ablation (RFA) did not meet the primary endpoint of the Phase III HEAT Study in patients with hepatocellular carcinoma (HCC), also known as primary liver cancer. Specifically, Celsion has determined, after conferring with its independent Data Monitoring Committee (DMC) that the HEAT Study...

2013-01-30 16:25:14

LAWRENCEVILLE, N.J., Jan. 30, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that it will host a conference call and webcast at 8:00 a.m. Eastern Time on Thursday, January 31, 2013 to present the top-line results from its pivotal Phase III HEAT Study with ThermoDox® in combination with radiofrequency ablation (RFA) in patients with intermediate hepatocellular carcinoma (HCC) versus those patients receiving...

2012-12-10 08:26:21

CAMBRIDGE, Mass., Dec. 10, 2012 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced Phase I clinical trial results for MM-302, the company's novel agent for the treatment of advanced HER2 positive (HER2+ or ErbB2+) breast cancer. The findings demonstrated preliminary safety and tolerability. A study of its potential companion imaging diagnostic was shown to predict treatment response in preclinical models. Data were presented at the 2012 CTRC-AACR San Antonio Breast...